Recent studies suggest that tumor-specific sympathetic denervation inhibits tumor progression (Magnon et al., 2013), contributes to tumor-induced changes in metabolism (Borniger et al., 2018), and reduces the expression of immune checkpoint molecules, such as programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and FOXP3 (Kamiya et al., 2019). The gene discussed is FOXP3; the disease is neoplasm.